198 related articles for article (PubMed ID: 28272674)
21. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence.
Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H
Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752
[TBL] [Abstract][Full Text] [Related]
22. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
23. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
[TBL] [Abstract][Full Text] [Related]
24. Disease outcomes for skull base and spinal chordomas: a single center experience.
Ahmed R; Sheybani A; Menezes AH; Buatti JM; Hitchon PW
Clin Neurol Neurosurg; 2015 Mar; 130():67-73. PubMed ID: 25590662
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
Bai J; Zhai Y; Wang S; Gao H; Du J; Wang J; Li M; Li C; Gui S; Zhang C; Sun Y; Zhang Y
World Neurosurg; 2017 Mar; 99():282-287. PubMed ID: 27916725
[TBL] [Abstract][Full Text] [Related]
26. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
28. Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma.
Zhai Y; Bai J; Wang S; Gao H; Li M; Li C; Gui S; Zhang Y
J Neurosurg; 2018 Dec; 129(6):1429-1437. PubMed ID: 29303447
[TBL] [Abstract][Full Text] [Related]
29. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
[TBL] [Abstract][Full Text] [Related]
30. [A clinicopathological and immunohistochemical study of 34 cases of chordoma].
Hu Y; Gao Y; Zhang X
Zhonghua Bing Li Xue Za Zhi; 1996 Jun; 25(3):142-4. PubMed ID: 9275666
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Factors and Survival Outcome in Patients with Chordoma in the United States: A Population-Based Analysis.
Lee IJ; Lee RJ; Fahim DK
World Neurosurg; 2017 Aug; 104():346-355. PubMed ID: 28457925
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.
Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J
World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.
Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
Eur Spine J; 2014 Nov; 23(11):2416-22. PubMed ID: 24929808
[TBL] [Abstract][Full Text] [Related]
34. Chordomas: Histopathological Study in View of Anatomical Location.
Cha YJ; Suh YL
J Korean Med Sci; 2019 Apr; 34(13):e107. PubMed ID: 30950252
[TBL] [Abstract][Full Text] [Related]
35. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis.
Bohman LE; Koch M; Bailey RL; Alonso-Basanta M; Lee JY
World Neurosurg; 2014 Nov; 82(5):806-14. PubMed ID: 25009165
[TBL] [Abstract][Full Text] [Related]
36. Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus.
Walker F; Abramowitz L; Benabderrahmane D; Duval X; Descatoire V; Hénin D; Lehy T; Aparicio T
Hum Pathol; 2009 Nov; 40(11):1517-27. PubMed ID: 19716155
[TBL] [Abstract][Full Text] [Related]
37. A comparison of cell-cycle markers in skull base and sacral chordomas.
Yakkioui Y; Temel Y; Creytens D; Jahanshahi A; Fleischeuer R; Santegoeds RG; Van Overbeeke JJ
World Neurosurg; 2014; 82(1-2):e311-8. PubMed ID: 23416769
[TBL] [Abstract][Full Text] [Related]
38. Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples.
Oono Y; Kuwata T; Takashima K; Shinmura K; Hori K; Yoda Y; Ikematsu H; Shitara K; Kinoshita T; Yano T
Gastric Cancer; 2019 Mar; 22(2):335-343. PubMed ID: 29951752
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
40. Skull base chordomas: clinical outcome in a consecutive series of 45 patients with long-term follow-up and evaluation of clinical and biological prognostic factors.
Boari N; Gagliardi F; Cavalli A; Gemma M; Ferrari L; Riva P; Mortini P
J Neurosurg; 2016 Aug; 125(2):450-60. PubMed ID: 26745472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
